vitiligo
Conditions
Interventions
Vitiligo patients group:None
Healthy control group:None
Sponsors
Department of Dermatology, Tongji Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for vitiligo patients: (1) Aged range from 4 to 60 years. (2) Patients with vitiligo who have been diagnosed by an experienced physician using wood lamps and who have completed various examinations and epidemiological investigations (according to the vitiligo Diagnosis and Treatment Consensus (2021 edition)). (3) The organ function level of the patient shall meet the following requirements: 1) Blood: neutrophil absolute count (ANC) >=2.0x10^9/L, platelet >=100x10^9/L, hemoglobin >=9g/dl; 2) Liver: bilirubin =60ml/min; (4) Patients of childbearing age must undergo a pregnancy test within one week before the test and the results are negative; (5) Understand and voluntarily sign written informed consent. 2. Inclusion criteria of healthy subjects: (1) Aged range from 4 to 60 years. (2) No history of vitiligo related diseases. (3) No clinically significant positive signs were found on physical examination. (4) Blood routine, stool routine, infectious disease, electrocardiogram, chest X-ray and abdominal B ultrasonography and other examinations found no abnormalities of clinical significance. (5) Subjects of childbearing age must undergo a pregnancy test within one week before the test and the result is negative. (6) Good compliance, willing to cooperate with the research, agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for vitiligo patients: (1) Patients with skin-related comorbidities, such as diabetes mellitus, pernacious anemia, malignant tumors, psoriasis, specific dermatitis, alopecia areata, severe infectious diseases, cardiopulmonary insufficiency, hepatorenal insufficiency, coagulation dysfunction or other serious systemic diseases; (2) Pregnancy or lactation; (3) Patient's organ system status: 1) Prior history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy, or any clinically proven active interstitial lung disease; 2) Evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, heart, liver or kidney disease), as determined by the investigator; 3) Any unstable systemic disease (including active infection, grade ? hypertension, unstable angina, congestive heart failure, liver or kidney or metabolic disease); 4) Patients who cannot receive oral medications, need intravenous high-energy nutrition, have undergone previous operations that affect absorption, or have active digestive tract ulcers; 5) A clear history of neurological or psychiatric disorders, including epilepsy or dementia; (4) Any other disease, neurological or metabolic disorder, evidence of physical examination or laboratory test results that reasonably suspect the presence of disease or the existence of a counterindication of the use of related drugs or the possibility of putting the patient at high risk of treatment-related complications; (5) The investigator believes that the patient is unlikely to complete the study or comply with the requirements of the study (for administrative or other reasons). 2. Exclusion criteria for healthy subjects: (1) Have received a blood transfusion or participated in other clinical trials in the past 6 months. (2) Pregnant or lactating subjects. (3) Severe cognitive and mental disorders. (4) Allergic constitution or known allergic to local anesthesia drugs. (5) Those with a history of drug abuse, illegal drug use or chronic alcoholism, or daily total alcohol intake > 50 g/d, which may affect the test results. (6) According to the judgment of the investigator, there is a low possibility of conducting the test (such as weak body, immune deficiency, etc.) or other conditions that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| exosome; | — |
Countries
China
Contacts
Public ContactDeng Yunhua
Department of Dermatology, Tongji Hospital
Outcome results
None listed